1. Home
  2. BGT vs IMMX Comparison

BGT vs IMMX Comparison

Compare BGT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Floating Rate Income Trust

BGT

BlackRock Floating Rate Income Trust

HOLD

Current Price

$11.32

Market Cap

320.3M

Sector

Finance

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$5.35

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGT
IMMX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.3M
306.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BGT
IMMX
Price
$11.32
$5.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
107.2K
1.5M
Earning Date
01-01-0001
11-07-2025
Dividend Yield
10.77%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.89
$1.34
52 Week High
$13.42
$7.73

Technical Indicators

Market Signals
Indicator
BGT
IMMX
Relative Strength Index (RSI) 49.73 49.40
Support Level $11.29 $5.46
Resistance Level $11.43 $6.09
Average True Range (ATR) 0.08 0.53
MACD 0.02 -0.17
Stochastic Oscillator 64.81 4.84

Price Performance

Historical Comparison
BGT
IMMX

About BGT BlackRock Floating Rate Income Trust

Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: